GPT and depressive symptom measurement: The symptoms leading to definitive interruption of treatment in order of frequency were: rash 11 (21.2%), urticarial reaction 8 (15.4%), angioedema 7 (13.5%), skin peeling 6 (11.5%), epigastric pain 6 (11.5%), bullous eruption 5 (9.6%), paraesthesia 3 (5.8%), drug reaction with eosinophilia and systemic symptoms 2 (3.8%), sleep disturbance 2 (3.8%), depression 1 (1.9%) and three times increase in baseline levels of alanine aminotransferase 1 (1.9%).